The Pancreatic Surgery Department at Zhongshan Hospital, affiliated to Fudan University, is among China's pioneering centers for pancreaticoduodenectomy. It has developed a distinctive "surgery-centered comprehensive diagnosis and treatment model for pancreatic tumors" and established a full surgical system encompassing open, laparoscopic, and robotic techniques. In 2005, it spearheaded nationwide efforts to organize Multi-disciplinary Team (MDT) diagnosis and treatment initiatives across different regions. In 2023, Zhongshan Pancreatic Surgery established the nation's first "Multi-disciplinary Team (MDT) Outpatient Clinic for Biliary and Pancreatic Tumor Liver Metastases," pioneering a collaborative approach across disciplines to enhance treatment outcomes. The department serves as the deputy head unit of the Pancreatic Surgery Group of the Chinese Medical Association's Surgical Branch, and is a key discipline under the Ministry of Education and a focal department of the national "211 Project."

In 2015, Zhongshan Pancreatic Surgery consolidated its institutional strengths to establish the "Zhongshan Pancreatic Tumor Center," integrating medical education, research, and multiple department collaboration. It was designated in 2022 as a national clinical quality control center for pancreatic cancer by the National Cancer Center and led the quality control inspection of pancreatic surgeries in Shanghai in 2024. The department has undertaken over 50 national-level projects, including major instrument projects funded by the National Natural Science Foundation and major projects of the Ministry of Science and Technology. It has led or participated in over 30 multi-center clinical studies both domestically and internationally, with over 300 SCI papers published in renowned international surgical and oncological journals and more than 10 invention patents. In 2023, it was the sole mainland Chinese institution involved in the formulation of international expert consensus on advanced pancreatic cancer treatment guidelines.

As one of the largest comprehensive pancreatic tumor treatment centers in China, the Zhongshan Pancreatic Surgery department annually performs over 1,200 pancreatic resection surgeries and offers comprehensive care to more than 20,000 patients with pancreatic tumors, focusing on discipline specialties such as "liver-pancreas combined resection (multi-organ combined surgery)," "expanded radical resection after conversion (transforming unresectable into resectable)," "minimally invasive surgery (precision and organ function preservation)," and "full-cycle management." It has received numerous awards including the first and second prizes for Shanghai Medical Science and Technology Award and recognition in the "Top Ten Innovative Medical Technologies" in Xiamen in 2022. It stands as a leading super-large-scale pancreatic tumor treatment center nationally and internationally.